1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31646
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFan, Guang-Han-
dc.contributor.authorZhang, Chen-Zhi-
dc.contributor.authorGao, Feng-Qiang-
dc.contributor.authorWei, Xu-Yong-
dc.contributor.authorLing, Sun-Bin-
dc.contributor.authorWang, Kai-
dc.contributor.authorWang, Jian-Guo-
dc.contributor.authorZheng, Shu-Sen-
dc.contributor.authorNikfarjam, Mehrdad-
dc.contributor.authorXu, Xiao-
dc.date2022-
dc.date.accessioned2023-01-12T01:48:45Z-
dc.date.available2023-01-12T01:48:45Z-
dc.date.issued2023-02-
dc.identifier.citationHepatobiliary & Pancreatic Diseases International: HBPD INT 2023; 22(1)en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/31646-
dc.description.abstractLiver transplantation (LT) is an effective treatment option for end-stage liver disease. Mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin, are widely used post LT.en_US
dc.language.isoeng-
dc.subjectHepatocellular carcinomaen_US
dc.subjectLiver transplantationen_US
dc.subjectMetabolic diseaseen_US
dc.subjectRapamycinen_US
dc.subjectTumor recurrenceen_US
dc.titleA mixed blessing for liver transplantation patients - Rapamycin.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleHepatobiliary & Pancreatic Diseases International: HBPD INTen_US
dc.identifier.affiliationDepartment of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.en_US
dc.identifier.affiliationState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer, Guangzhou 510060, China.en_US
dc.identifier.affiliationDepartment of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou 310006, China; Institute of Organ Transplantation, Zhejiang University, Hangzhou 310003, China.en_US
dc.identifier.affiliationInstitute of Organ Transplantation, Zhejiang University, Hangzhou 310003, China; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou 310000, China; NHC Key Laboratory of Combined Multi-Organ Transplantation, Hangzhou 310003, China.en_US
dc.identifier.affiliationSurgery (University of Melbourne)en_US
dc.identifier.affiliationZhejiang University School of Medicine, Hangzhou 310058, China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou 310006, China; Institute of Organ Transplantation, Zhejiang University, Hangzhou 310003, China; Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China.en_US
dc.identifier.affiliationInstitute of Organ Transplantation, Zhejiang University, Hangzhou 310003, China.en_US
dc.identifier.doi10.1016/j.hbpd.2022.10.004en_US
dc.type.contentTexten_US
dc.identifier.pubmedid36328894-
local.name.researcherNikfarjam, Mehrdad
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
crisitem.author.deptSurgery (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Dec 5, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.